Hikal growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−7.9%+4.2%−11.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−32.9%+23.0%+3.9%
−70.8%+29.8%+0.9%
−153.7%+30.5%−11.2%
−153.8%+30.5%−11.3%
−6.5%+1.7%+4.3%
−5.0%+6.3%+4.8%
+7.7%+50.2%−40.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HIKAL₹202.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,496 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-11.8+4.2-7.9—
EBITDA Growth—+3.9+23.0-32.9—
EBIT Growth—+0.9+29.8-70.8—
Net Income Growth—-11.2+30.5-153.7—
EPS Growth—-11.3+30.5-153.8—
Total Assets Growth—+4.3+1.7-6.5—
Total Equity Growth—+4.8+6.3-5.0—
Cash from Operations Growth—-40.8+50.2+7.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.